Literature DB >> 33822472

Longevity of the novel ConvaTec infusion set with Lantern technology.

Rayhan A Lal1,2,3, Liana Hsu1, Jian Zhang2, Pernelle K Schøndorff4, Matthias Heschel4, Bruce Buckingham1,3.   

Abstract

Current insulin infusion sets are approved for only 2-3 days. The novel ConvaTec infusion set with Lantern technology is designed to extend infusion set wear time. The goal of this pilot study was to evaluate the duration of wear for this set. This was a pilot safety study in adults with type 1 diabetes using tethered insulin pumps. Participants inserted the set and wore it for 10 days or until failure. Among 24 participants, two were excluded. Forty-five per cent of the sets lasted 10 days. Median wear time was 9.1 (7.1, 10.0) days. Among 12 premature failures, six (50%) involved adhesive failures, four (33%) hyperglycaemia unresponsive to correction, one (8%) hyperglycaemia with ketones and one (8%) infection. Average CGM glucose per day of infusion set wear showed a statistically significant increase over time, while total daily insulin over the same period did not change. In this pilot study, the duration of wear for the novel infusion set exceeded previously reported commercial sets (P < .001). This extended wear technology may eventually allow for a combined glucose sensor and infusion set.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  CSII; insulin pump therapy; insulin therapy; type 1 diabetes

Mesh:

Substances:

Year:  2021        PMID: 33822472      PMCID: PMC8720264          DOI: 10.1111/dom.14395

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.408


  13 in total

1.  Randomized trial of infusion set function: steel versus teflon.

Authors:  Parul J Patel; Kari Benasi; Gina Ferrari; Mark G Evans; Satya Shanmugham; Darrell M Wilson; Bruce A Buckingham
Journal:  Diabetes Technol Ther       Date:  2013-10-03       Impact factor: 6.118

2.  Fatalities Due to Failure of Continuous Subcutaneous Insulin Infusion Devices: A Report of Six Cases.

Authors:  Andrew Ziegler; Timothy Williams; Nicole Yarid; Daniel L Schultz; Elizabeth A Bundock
Journal:  J Forensic Sci       Date:  2018-06-25       Impact factor: 1.832

3.  A Prospective Study of Insulin Infusion Set Use for up to 7 Days: Early Replacement Reasons and Impact on Glycemic Control.

Authors:  Delia Waldenmaier; Eva Zschornack; Andreas Buhr; Stefan Pleus; Cornelia Haug; Guido Freckmann
Journal:  Diabetes Technol Ther       Date:  2020-04-06       Impact factor: 6.118

4.  Development of a Single-Site Device for Conjoined Glucose Sensing and Insulin Delivery in Type-1 Diabetes Patients.

Authors:  Mathias Tschaikner; Amra Simic; Miro Jungklaus; Martin Fritz; Martin Ellmerer; Thomas R Pieber; Werner Regittnig
Journal:  IEEE Trans Biomed Eng       Date:  2019-05-27       Impact factor: 4.538

5.  Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.

Authors:  B W Bode; P Strange
Journal:  Diabetes Care       Date:  2001-01       Impact factor: 19.112

6.  First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus.

Authors:  M Rumpler; J K Mader; J P Fischer; R Thar; J M Granger; F Deliane; I Klimant; F Aberer; F Sinner; T R Pieber; M Hajnsek
Journal:  Biosens Bioelectron       Date:  2016-08-13       Impact factor: 10.618

7.  Performance and acceptability of a combined device for insulin infusion and glucose sensing in the home setting.

Authors:  Kirsten Nørgaard; John Shin; John B Welsh; Hans Gjessing
Journal:  J Diabetes Sci Technol       Date:  2015-01-14

8.  Novel Single-Site Device for Conjoined Glucose Sensing and Insulin Infusion: Performance Evaluation in Diabetes Patients During Home-Use.

Authors:  Mathias Tschaikner; Kevin Powell; Miro Jungklaus; Martin Fritz; Martin Ellmerer; Roman Hovorka; Steve Lane; Thomas R Pieber; Werner Regittnig
Journal:  IEEE Trans Biomed Eng       Date:  2019-06-27       Impact factor: 4.538

9.  Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3.

Authors:  Volkmar Schmid; Cloth Hohberg; Marcus Borchert; Thomas Forst; Andreas Pfützner
Journal:  J Diabetes Sci Technol       Date:  2010-07-01

10.  Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion.

Authors:  Tina K Thethi; Ajay Rao; Haytham Kawji; Tilak Mallik; C Lillian Yau; Uwe Christians; Vivian Fonseca
Journal:  J Diabetes Complications       Date:  2009-04-23       Impact factor: 2.852

View more
  5 in total

1.  Improving the Patient Experience With Longer Wear Infusion Sets Symposium Report.

Authors:  Kevin T Nguyen; Nicole Y Xu; Bruce A Buckingham; Sarnath Chattaraj; Ohad Cohen; Lutz Heinemann; John Pickup; Jannet Svensson; Robert A Vigersky; Jenise C Wong; Ralph Ziegler
Journal:  J Diabetes Sci Technol       Date:  2022-02-28

Review 2.  Current Status and Emerging Options for Automated Insulin Delivery Systems.

Authors:  Gregory P Forlenza; Rayhan A Lal
Journal:  Diabetes Technol Ther       Date:  2022-03-14       Impact factor: 7.337

3.  Advances in Insulin Pump Infusion Sets Symposium Report.

Authors:  Jennifer Y Zhang; Trisha Shang; Sarnath Chattaraj; Ohad Cohen; Matthias Heschel; Robert A Vigersky; Lutz Heinemann; Kirsten Nørgaard; Jannet Svensson; Bruce Buckingham; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2021-03-11

4.  Insulin induces a progressive increase in the resistance of subcutaneous tissue to fluid flow: Implications for insulin pump therapy.

Authors:  Werner Regittnig; Mathias Tschaikner; Alexandru-Cristian Tuca; Amra Simic; Jürgen Feiel; Roland Schaller-Ammann; Alexander H Licht; Miró Jungklaus; Thomas R Pieber
Journal:  Diabetes Obes Metab       Date:  2021-11-17       Impact factor: 6.408

5.  Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial.

Authors:  Ron Brazg; Satish K Garg; Anuj Bhargava; James R Thrasher; Kashif Latif; Bruce W Bode; Timothy S Bailey; Barry S Horowitz; Arvind Cavale; Yogish C Kudva; Kevin B Kaiserman; George Grunberger; John Chip Reed; Sarnath Chattaraj; Gina Zhang; John Shin; Vivian Chen; Scott W Lee; Toni L Cordero; Andrew S Rhinehart; Robert A Vigersky; Bruce A Buckingham
Journal:  Diabetes Technol Ther       Date:  2022-03-24       Impact factor: 7.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.